Aurobindo Pharma has signed a non-exclusive, royalty-free voluntary licensing agreement with MSD (trade name of Merck & Co., Inc.) to supply generic alimtravir to 129 low- and middle-income countries (LMICs). Announced on July 24, 2026, the deal enables the company to manufacture the drug, which targets regions accounting for the majority of new HIV diagnoses globally. This early execution, occurring before the completion of Phase 3 trial enrollment, marks a first in HIV prevention, allowing stakeholders to plan for scale-up operations immediately upon regulatory approval.

The agreement is subject to applicable regulatory approvals and requirements. Aurobindo Pharma joins a select group of global generic manufacturers in signing such agreements, aiming to meet internationally recognized standards once regulatory hurdles are cleared. The company’s corporate office is located in Hyderabad, Telangana.

Key Deal Parameters

The following table outlines the core terms of the licensing agreement between Aurobindo Pharma and MSD:

Leadership Perspectives

Umesh K, Associate President & Head – Global Access & Licensing at Aurobindo Pharma, stated that expanding access to high-quality, affordable medicines remains central to the company's purpose. He noted that the collaboration reflects a commitment to partnering with innovators to accelerate equitable access to potential new therapies. The goal is to make alimtravir available across eligible LMICs, helping strengthen global efforts towards HIV prevention.

Gregg Szabo, Senior Vice President, Global HIV Marketing at MSD, expressed pleasure in working with Aurobindo and other manufacturers involved in these voluntary licensing agreements. He emphasized that this early action will help stakeholders across the HIV response plan for the scale-up needed to reach people who could benefit from HIV prevention, following necessary regulatory approvals.

Strategic Significance

The focus on 129 LMICs highlights a strategic concentration on markets that account for the majority of new HIV diagnoses globally. By securing rights before Phase 3 trials conclude, Aurobindo Pharma positions itself to move rapidly upon approval, bypassing typical post-approval licensing delays. This proactive approach underscores the importance of speed-to-market in public health interventions, particularly for preventive therapies in resource-constrained settings.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE406A01037/22ca7b243fd94d73.pdf

aurobindo pharma subsidiary Apitoria Pharma Private Limited has approved the acquisition of an 80% stake in A1 Biochem Group for USD 17 million, marking a strategic expansion into contract research services. The Board of Apitoria finalized the deal on July 23, 2026, aiming to integrate front-end research capabilities with its existing large-scale API manufacturing operations. This acquisition enables the creation of a dedicated Contract Research, Development and Manufacturing (CRDMO) platform, allowing for longer lifecycle engagement with pharmaceutical clients and biotechs primarily in the USA.

The transaction is structured under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Apitoria will invest USD 13.6 million for its 80% ownership share, subject to closing adjustments. The remaining 20% stake will be retained by the existing promoter of A1 Biochem Group. Upon completion, A1 Biochem Labs (India) Private Limited will hold 100% ownership of A1 Biochem Labs LLC in the USA and acquire the business of A1 Biochem Research (India) Private Limited. The deal is expected to close within 90 to 120 days, subject to customary regulatory approvals and conditions prescribed in the Definitive Agreements.

A1 Biochem Group operates as a Contract Research Organization providing chemistry services including custom synthesis, medicinal chemistry, route scouting, analytical development, and rapid process scale-up. The group maintains scientific laboratories in Wilmington, North Carolina, and Hyderabad, India, employing over 90 scientists and utilizing more than 50 fume hoods. Dr. Rajendra Gadikota, who leads the group with over 25 years of experience, will continue with the organization post-acquisition. The target business serves a client base of over 50 entities and has completed more than 800 projects in the USA.

Financial Profile of Target Entity

The financial performance of A1 Biochem Group over the last three fiscal years demonstrates significant growth in turnover, followed by stabilization in FY25-26. The group generated substantial EBITDA margins relative to its revenue base.

The acquisition does not constitute a related party transaction, as the promoters or group companies of Aurobindo Pharma have no prior interest in the target entities. The consideration is entirely cash-based. By integrating A1 Biochem’s CRO platform, Apitoria seeks to complement its current API manufacturing business, offering end-to-end solutions from early-stage research to commercial-scale production.

Strategic Implications

This acquisition aligns with the company’s objective to deepen its presence in the API value chain. By acquiring established R&D capabilities and an existing client network, Aurobindo Pharma reduces the time required to build such infrastructure organically. The integration of A1 Biochem’s US-based laboratory presence strengthens the company’s ability to serve North American clients directly, potentially enhancing revenue stability through long-term service contracts. The retention of key leadership, including Dr. Gadikota, ensures continuity in scientific operations and client relationships during the transition period.